As Chief Medical Officer, David Oldach oversees translational and early clinical drug development activities across a broad spectrum of diseases influenced by autoimmunity within the arenas of nephrology, rheumatology, transplant immunology and neurology.
David Oldach joined Visterra in 2017 and has more than 25 years of experience in the biotechnology industry and academia. Prior to joining Visterra, David served as Chief Medical Officer at Cempra Pharmaceuticals developing antibiotics for multiple indications. Previously he served as Director of Clinical Research at Gilead, working in HCV and HBV antiviral drug development. Prior to joining industry, David was on the faculty of the University of Maryland School of Medicine, serving as Infectious Diseases Division Chief at the Baltimore Veterans Affairs Medical Center, with a joint appointment as Investigator in the Institute of Human Virology. David has authored more than 75 manuscripts, invited editorials, and book chapters across a range of disease topics.
David received his M.D., magna cum laude, from the University of Maryland School of Medicine, trained in Internal Medicine at Massachusetts General Hospital and in Infectious Diseases at Johns Hopkins Hospital.
